Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14650585 | 0.81 | FLT3 (0.51) | CDK2EPHB4GSK3BDYRK1ASYK | |
| SCHEMBL582624 | 0.80 | EPHB4 (0.58) | CDK4CDK2EPHB4SLC2A1GSK3B | |
| SCHEMBL14635042 | 0.80 | EPHB4 (0.61) | EPHB4SYKEGFRCYP1A2CYP3A4 | |
| SCHEMBL14650594 | 0.80 | NPC1 (0.58) | SYKSRC | |
| SCHEMBL14650586 | 0.80 | EPHB4 (0.61) | CDK2EPHB4GSK3BSYKAURKA | |
| Hydrochloric Acid SCHEMBL14634785 | 0.79 | AURKA (0.45) | CDK2EPHB4SYKIGF1REGFR | |
| SCHEMBL14635413 | 0.79 | LCK (0.63) | SYK | |
| SCHEMBL14634890 | 0.79 | EGFR (0.44) | CDK2GSK3BDYRK1ASYKCDC7 | |
| SCHEMBL14650711 | 0.77 | SYK (0.45) | CDK2EPHB4GSK3BDYRK1ASYK | |
| SCHEMBL14650618 | 0.77 | TNNI3K (0.53) | CDK2EPHB4SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | CDK4 63/4885CDK2 1/4885EPHB4 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.